EHAB vs RARE · rev $1.03B vs rev $350.0M
Enhabit Inc. (EHAB) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Enhabit Inc. (EHAB) is a medical care facilities company listed on NYSE.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported EHAB revenue for 2024-12-31 was $1.03B. Net income was -$154.0M. Revenue was down 1.1% from 2023-12-31 to 2024-12-31. EHAB currently screens at market cap $706.9M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
EHAB currently screens at market cap $706.9M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the EHAB and RARE stock pages for the full models.
Not investment advice.